Jack Scannell has researched biomedical R&D productivity from financial, regulatory, and scientific perspectives, focusing on the contrast between cheaper and better scientific inputs, and the long-term decline in R&D output efficiency. He is now the CEO of Etheros Pharmaceuticals, a pre-clinical stage company that is developing new chemistries for neurodegenerative diseases. He is Associate of the Innogen Institute and of the Department of Science, Technology, and Innovation Studies at the University of Edinburgh. He had senior roles in drug and biotech investment at UBS and at Sanford Bernstein. He was Head of Discovery Research at e-Therapeutics PLC, an Oxford-based biotechnology firm.. He has a PhD in Physiology from Oxford University and a degree in Medical Sciences from Cambridge University.